Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference

TWST 12.19.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-13
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur TWST Tweets

About Gravity Analytica

Recent News

  • 02.03.2025 - Fiscal 2025 First Quarter Financial Results Conference Call
  • 01.22.2025 - Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025
  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 01.10.2025 - 144 Report of proposed sale of securities

Press Release Details

Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024
PDF Version

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Dec. 19, 2024--Twist Bioscience Corporation(NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Emily M. Leproust, Ph.D., CEO and co-founder ofTwist Bioscience, will present at the 43rdAnnualJ.P. Morgan Healthcare ConferenceonMonday, January 13, 2025at5:15 p.m. Pacific TimeinSan Francisco, California.

The presentation will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's websitehere. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events.

AboutTwist Bioscience Corporation

Twist Bioscienceis a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us onLinkedIn|X|YouTube|Instagram

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241219026063/en/

For Investors:Angela BittingSVP, Corporate Affairs925-202-6211abitting@twistbioscience.com

For Media:Amanda HoulihanCommunications Manager774-265-5334ahoulihan@twistbioscience.com

Source:Twist Bioscience Corporation

  • Print Page
  • Email Page
  • Email Alerts
  • RSS Feeds
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com